Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

0.7036
+0.04226.38%
Post-market: 0.6701-0.0335-4.76%18:36 EST
Volume:1.23M
Turnover:831.74K
Market Cap:205.56M
PE:-0.88
High:0.7092
Open:0.6600
Low:0.6300
Close:0.6614
Loading ...

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
19 Feb

Following a 67% decline over last year, recent gains may please Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners

Simply Wall St.
·
17 Feb

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake

Simply Wall St.
·
31 Jan

Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why

Zacks
·
23 Jan

Lyell Immunopharma price target lowered to 60c from $1 at BofA

TIPRANKS
·
12 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)

TIPRANKS
·
11 Jan

After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

Zacks
·
30 Dec 2024

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)

TIPRANKS
·
24 Dec 2024

Lyell Immunopharma presents positive data from Phase 1-2 IMPT-314 study

TIPRANKS
·
10 Dec 2024

BRIEF-Lyell Immunopharma Says Impt-314 Receives Fast Track Designation From FDA

Reuters
·
10 Dec 2024

Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 Ash Annual Meeting

THOMSON REUTERS
·
10 Dec 2024

Lyell Immunopharma Inc - Impt-314 Receives Fast Track Designation From FDA

THOMSON REUTERS
·
10 Dec 2024

BRIEF-Lyell Immunopharma Files Prospectus Related To Resale From Time To Time By Selling Stockholders Of Up To 37.5 Million Shares Of Common Stock

Reuters
·
30 Nov 2024

Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know

Zacks
·
15 Nov 2024

Lyell Immunopharma Price Target Maintained With a $1.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges

TIPRANKS
·
12 Nov 2024